David Saggau is an Ophthalmology physician affiliated with Wolfe Eye Clinic. OpenAlex indexes 10 publications with 278 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6200 Westown Pkwy
West Des Moines, IA 502667705
Telephone
515-233-8685Registry record last updated 15 Feb 2018.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Sight Sciences, Inc.Program year20251 payment
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
- Sight Sciences, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
98.3%Antineovascularisation agents93.6%Faricimab-svoa100%Part B, office-administered≥180 patientsVascular Endothelial Growth Factor Inhibitor4.3%Ranibizumab100%Part B, office-administered≥116 patients+ 3 more classes in this area
Cancer & immunology
1.6%Vascular Endothelial Growth Factor Inhibitor1.6%Aflibercept100%Part B, office-administered≥116 patientsCardiovascular
0.1%Beta blocker0.1%Timolol Maleate100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- High-Dose Aflibercept for Neovascular AMD and DME in Suboptimal Responders to Standard-Dose Aflibercept
Journal of VitreoRetinal Diseases
2023 - Management of CAPN5 ADNIV with intensive combination anti-VEGF and corticosteroid therapy
Investigative Ophthalmology & Visual Science
2019 - RIFAMPIN INDUCED HEPATOTOXICITY DURING TREATMENT FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
Retinal Cases & Brief Reports
2013
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”